Pharmaceutical Information |
Drug Name |
Natalizumab |
Drug ID |
BADD_D01537 |
Description |
Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006. |
Indications and Usage |
For treatment of multiple sclerosis. |
Marketing Status |
Prescription |
ATC Code |
L04AA23 |
DrugBank ID |
DB00108
|
KEGG ID |
D06886
|
MeSH ID |
D000069442
|
PubChem ID |
Not Available
|
TTD Drug ID |
Not Available
|
NDC Product Code |
64406-008 |
Synonyms |
Natalizumab | Tysabri | Antegren |
|
Chemical Information |
Molecular Formula |
Not Available |
CAS Registry Number |
189261-10-7 |
SMILES |
Not Available |
Chemical Structure |
|
|
ADR Related Proteins Induced by Drug |
ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
Not Available | Not Available | Not Available | Not Available | Not Available |
|
ADRs Induced by Drug |
ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
Tooth infection | 11.01.04.004; 07.09.01.004 | - | - | | Seasonal allergy | 22.04.04.008; 10.01.04.001; 06.04.01.013 | - | - | Not Available | Thermal burn | 12.05.04.001 | - | - | | Limb injury | 12.01.09.008 | - | - | Not Available |
|
|
|